Chapter 12. A New Generation of Drugs in Cancer Treatment: Molecularly Targeted Therapies

  1. Arthur B. Pardee3,4 and
  2. Gary S. Stein5
  1. Thomas O'Hare1,
  2. Christopher A. Eide1 and
  3. Michael W. Deininger2

Published Online: 26 MAR 2008

DOI: 10.1002/9780470374252.ch12

The Biology and Treatment of Cancer: Understanding Cancer

The Biology and Treatment of Cancer: Understanding Cancer

How to Cite

O'Hare, T., Eide, C. A. and Deininger, M. W. (2008) A New Generation of Drugs in Cancer Treatment: Molecularly Targeted Therapies, in The Biology and Treatment of Cancer: Understanding Cancer (eds A. B. Pardee and G. S. Stein), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470374252.ch12

Editor Information

  1. 3

    Department of Biological Chemistry, Harvard University, Dana-Farber Cancer Institute, USA

  2. 4

    Harvard Medical School, Dana-Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts, USA

  3. 5

    Department of Cell Biology, UMASS Memorial Cancer Center, University of Massachusetts Medical School, Worcester, Massachusetts, USA

Author Information

  1. 1

    Howard Hughes Medical Institute, Oregon Health & Science University, Cancer Institute, Portland, Oregon, USA

  2. 2

    Oregon Health & Science University, Center for Hematologic Malignancies, Portland, Oregon, USA

Publication History

  1. Published Online: 26 MAR 2008
  2. Published Print: 19 DEC 2008

ISBN Information

Print ISBN: 9780470009581

Online ISBN: 9780470374252

SEARCH

Keywords:

  • molecularly targeted therapy - inhibiting BCR–ABL IN CML, the gold standard;
  • targeting HER2-positive breast cancer;
  • BRAF V600E mutation in melanoma

Summary

This chapter contains sections titled:

  • Introduction

  • Inhibiting Bcr–Abl in CML: The Gold Standard of Molecularly Targeted Therapy

  • EGFR in Non-Small-Cell Lung Cancer

  • BRAF V600E Mutation in Melanoma

  • JAK2 in Polycythemia Vera

  • Therapeutic Strategies for Myelodysplastic Syndromes

  • Closing Thoughts

  • References